LEADER 01124nam2-2200361---450- 001 990006065620203316 005 20150903115154.0 012 $ar-si tia. uiad sigl (3) 1819 (A)$2fei$5SA0186 035 $a000606562 035 $aUSA01000606562 035 $a(ALEPH)000606562USA01 035 $a000606562 100 $a20150825d1819----km-y0itay50------ba 101 $aita 102 $aIT 105 $a||||||||001yy 200 1 $a<> Parte prosaica 210 $aNapoli$cdalla stamperia della Societą Tipografica$d1819 215 $aXII [i.e. X], 296, [8] p.$d8° 307 $aSegnatura: [pigreco]4 [chi]1 (1)-(19)8 410 0$12001 454 1$12001 461 1$1001000606561$12001$aCorso analitico elementare di Letteratura di Marco Gatti 700 1$aGATTI,$bMarco$f$0620780 801 0$aIT$bsalbc$gISBD 912 $a990006065620203316 951 $aXV.7. 209 1$b82 FCar$cXV.7.$d378622 959 $aBK 969 $aFCAR 979 $aGENEROSO$b90$c20150825$lUSA01$h1050 979 $aGENEROSO$b90$c20150903$lUSA01$h1151 996 $aParte prosaica$91102210 997 $aUNISA LEADER 01461nam 2200469 450 001 9910819940903321 005 20230803211314.0 010 $a1-78084-463-8 035 $a(CKB)4230000000000008 035 $a(MiAaPQ)EBC5092359 035 $a(Au-PeEL)EBL5092359 035 $a(CaPaEBR)ebr11451901 035 $a(OCoLC)1006403222 035 $a(EXLCZ)994230000000000008 100 $a20171107h20142014 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 00$aCYP2D $egenetics, pharmacology and clinical relevance /$feditor, Pierre Baumann 210 1$aLondon, England :$cFuture Medicine Ltd,$d2014. 210 4$d©2014 215 $a1 online resource (153 pages) $ccolor illustrations, tables 311 $a1-78084-464-6 311 $a1-78084-462-X 320 $aIncludes bibliographical references at the end of each chapters and index. 606 $aCytochrome P-450$xPhysiological effect 606 $aCytochrome P-450$xGenetics 606 $aCytochrome P-450$xTherapeutic use 615 0$aCytochrome P-450$xPhysiological effect. 615 0$aCytochrome P-450$xGenetics. 615 0$aCytochrome P-450$xTherapeutic use. 676 $a574.1925 702 $aBaumann$b Pierre 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910819940903321 996 $aCYP2D$94068017 997 $aUNINA